Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 1
1990 1
1991 3
1992 8
1993 1
1994 7
1995 11
1996 7
1997 8
1998 6
1999 1
2000 4
2002 2
2003 1
2004 2
2005 1
2006 1
2009 1
2010 1
2014 1
2015 3
2019 1
2022 1
2023 2
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J, Marty FM, Papanicolaou GA, Silveira FP, Witzke O, Wu J, Sundberg AK, Fournier M; SOLSTICE Trial Investigators. Avery RK, et al. Clin Infect Dis. 2022 Sep 10;75(4):690-701. doi: 10.1093/cid/ciab988. Clin Infect Dis. 2022. PMID: 34864943 Free PMC article. Clinical Trial.
METHODS: In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for …
METHODS: In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomize …
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Wagstaff AJ, Bryson HM. Wagstaff AJ, et al. Drugs. 1994 Aug;48(2):199-226. doi: 10.2165/00003495-199448020-00007. Drugs. 1994. PMID: 7527325 Review.
Aciclovir-resistant herpes simplex infections in immunocompromised patients have also been treated successfully with foscarnet. Almost 90% of a foscarnet dose is excreted in the urine. Reversible nephrotoxicity is common during foscarnet therapy, but may be r …
Aciclovir-resistant herpes simplex infections in immunocompromised patients have also been treated successfully with foscarnet. Almos …
Foscarnet Versus Ganciclovir for Severe Congenital Cytomegalovirus Infection: Short- and Long-Term Follow-Up.
Nigro G, Buzzi M, Catenaro M, Coclite E, Muselli M. Nigro G, et al. Viruses. 2025 May 17;17(5):720. doi: 10.3390/v17050720. Viruses. 2025. PMID: 40431731 Free PMC article. Clinical Trial.
Nine and five infants, belonging to the foscarnet or ganciclovir group, respectively, had abnormal hearing. One infant in each group also had chorioretinitis. ...Hearing was normal in four of the twelve children treated with foscarnet, seven of the twelve children t …
Nine and five infants, belonging to the foscarnet or ganciclovir group, respectively, had abnormal hearing. One infant in each group …
Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.
Jabs DA. Jabs DA. Infect Agents Dis. 1995 Sep;4(3):131-42. Infect Agents Dis. 1995. PMID: 8548191 Review.
Ganciclovir, a nucleoside analog, and foscarnet, a pyrophosphate analog, are both effective in controlling CMV retinitis. A randomized, controlled, comparative trial of foscarnet and ganciclovir demonstrated that they were equivalent in terms of controlling CMV reti …
Ganciclovir, a nucleoside analog, and foscarnet, a pyrophosphate analog, are both effective in controlling CMV retinitis. A randomize …
Antiviral treatment for acute retinal necrosis: A systematic review and meta-analysis.
Putera I, Ridwan AS, Dewi M, Cifuentes-González C, Rojas-Carabali W, Sitompul R, Edwar L, Susiyanti M, Aziza Y, Pavesio C, Chee SP, Mahendradas P, Biswas J, Kempen JH, Gupta V, de-la-Torre A, La Distia Nora R, Agrawal R. Putera I, et al. Surv Ophthalmol. 2024 Jan-Feb;69(1):67-84. doi: 10.1016/j.survophthal.2023.09.004. Epub 2023 Sep 27. Surv Ophthalmol. 2024. PMID: 37774799 Free article.
Interventions for prevention of herpes simplex labialis (cold sores on the lips).
Chi CC, Wang SH, Delamere FM, Wojnarowska F, Peters MC, Kanjirath PP. Chi CC, et al. Cochrane Database Syst Rev. 2015 Aug 7;2015(8):CD010095. doi: 10.1002/14651858.CD010095.pub2. Cochrane Database Syst Rev. 2015. PMID: 26252373 Free PMC article.
There was moderate quality evidence from a single RCT that topical foscarnet 3% cream has little effect in preventing HSL (RR 1.08, 95% CI 0.82 to 1.40; n = 295).The efficacy of long-term use of topical aciclovir cream was uncertain. ...
There was moderate quality evidence from a single RCT that topical foscarnet 3% cream has little effect in preventing HSL (RR 1.08, 9 …
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.
Chou S, Alain S, Cervera C, Chemaly RF, Kotton CN, Lundgren J, Papanicolaou GA, Pereira MR, Wu JJ, Murray RA, Buss NE, Fournier M. Chou S, et al. J Infect Dis. 2024 Feb 14;229(2):413-421. doi: 10.1093/infdis/jiad293. J Infect Dis. 2024. PMID: 37506264 Free PMC article. Clinical Trial.
RESULTS: At baseline, genotypic testing revealed resistance to ganciclovir, foscarnet, or cidofovir in 56% of patients receiving maribavir and 68% receiving IAT, including 9 newly phenotyped mutations. ...
RESULTS: At baseline, genotypic testing revealed resistance to ganciclovir, foscarnet, or cidofovir in 56% of patients receiving mari …
Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
Aweeka FT, Gambertoglio JG, Kramer F, van der Horst C, Polsky B, Jayewardene A, Lizak P, Emrick L, Tong W, Jacobson MA. Aweeka FT, et al. Clin Pharmacol Ther. 1995 Apr;57(4):403-12. doi: 10.1016/0009-9236(95)90209-0. Clin Pharmacol Ther. 1995. PMID: 7712668 Clinical Trial.
INTRODUCTION: The use of foscarnet and ganciclovir as a combination treatment for cytomegalovirus retinitis is increasing because of limitations associated with single agent therapy. ...For regimen A, 60 mg/kg intravenous foscarnet and 3.75 mg/kg ganciclovir were se …
INTRODUCTION: The use of foscarnet and ganciclovir as a combination treatment for cytomegalovirus retinitis is increasing because of …
Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes.
Lim KB, Doraisingham S, Thirumoorthy T, Lee CT, Ling AE, Tan T. Lim KB, et al. Ann Acad Med Singap. 1986 Oct;15(4):617-22. Ann Acad Med Singap. 1986. PMID: 2952046 Clinical Trial.
An antiviral effect of foscarnet was evident. The percentage of positive viral cultures found after starting treatment was 15% in the foscarnet-treated group compared to 44% in the placebo-treated group (p = 0.01). Treatment with foscarnet cream was not assoc …
An antiviral effect of foscarnet was evident. The percentage of positive viral cultures found after starting treatment was 15% in the …
Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial.
Hardy WD. Hardy WD. Am J Med. 1992 Feb 14;92(2A):30S-35S. doi: 10.1016/0002-9343(92)90335-9. Am J Med. 1992. PMID: 1531285 Clinical Trial.
A recently completed dose-comparative trial of foscarnet in AIDS patients with acyclovir-resistant HSV has confirmed the safety and efficacy of two doses of foscarnet (40 mg/kg every 8 or 12 hours) in the treatment of this disease, as well as providing preliminary e …
A recently completed dose-comparative trial of foscarnet in AIDS patients with acyclovir-resistant HSV has confirmed the safety and e …
79 results